Melissa L. Johnson

发表

Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2012, Cancer.

A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

M. Kris, C. Azzoli, W. Pao, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.

Melissa L. Johnson, J. Wheler, A. Seidman, 2006, Seminars in oncology.

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Ronglai Shen, Marc Ladanyi, M. Ladanyi, 2012, Clinical Cancer Research.

FGFR3–TACC3: A novel gene fusion in cervical cancer

Emily Berry, Alvaro Restrepo, Melissa L. Johnson, 2015, Gynecologic oncology reports.

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Melissa L. Johnson, A. El-Khoueiry, J. Rodon, 2021, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

P. Jänne, Melissa L. Johnson, S. Peters, 2015 .

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinoma.

M. Ladanyi, C. Sima, M. Kris, 2010 .

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

B. Taylor, M. Ladanyi, A. Drilon, 2020, Clinical Cancer Research.

Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Susan M. Chang, J. Meyerhardt, R. Schilsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies

R. Salgia, Melissa L. Johnson, R. Knoblauch, 2020, JTO clinical and research reports.

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

G. Scagliotti, H. Wakelee, F. Hirsch, 2022, Journal of Thoracic Oncology.

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

L. Schwartz, R. Govindan, J. Neal, 2022, Journal for ImmunoTherapy of Cancer.

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.

Melissa L. Johnson, F. McCormick, C. Lindsay, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers

C. Sima, M. Zauderer, M. Kris, 2016, PloS one.

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Robert W. Hsieh, Melissa L. Johnson, L. Paz-Ares, 2020 .

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.

Robert W. Hsieh, Melissa L. Johnson, J. Yang, 2022, The Lancet. Oncology.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer

A. Shaw, Melissa L. Johnson, E. Felip, 2020, Targeted Oncology.

Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findings

Suzanne F. Jones, Melissa L. Johnson, L. Hart, 2016 .

Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.

Melissa L. Johnson, B. Besse, P. Garrido, 2020, Lung cancer.

LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer.

Jie Yang, A. Drilon, M. Tsuboi, 2022, Future oncology.

Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

Craig B. Davis, C. Chung, Melissa L. Johnson, 2019, Journal of Immunotherapy for Cancer.

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

E. Smit, J. Heymach, Keunchil Park, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

D. Gandara, Melissa L. Johnson, S. Novello, 2022, Nature Medicine.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation

S. Ou, J. Christensen, Melissa L. Johnson, 2020, European Journal of Cancer.

A Phase 1 – 2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021 .

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study

N. Reinmuth, Melissa L. Johnson, B. Cho, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation

Melissa L. Johnson, E. Haura, P. Cassier, 2022, The oncologist.

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

R. Salgia, Melissa L. Johnson, V. Papadimitrakopoulou, 2019, Journal of Clinical Oncology.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell‐based vaccines

Melissa L. Johnson, T. Gajewski, T. C. Manning, 2003, Journal of leukocyte biology.

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth.

James J Foti, E. Jaffee, Kwok-Kin Wong, 2021, Cancer discovery.

Addressing resistance to immune checkpoint inhibitor therapy - an urgent unmet need.

Melissa L. Johnson, S. Hu-Lieskovan, G. Malouf, 2021, Future oncology.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.

A. Drilon, Keunchil Park, Y. Ohe, 2020, The New England journal of medicine.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

E. Smit, Melissa L. Johnson, E. Felip, 2022, Journal of Clinical Oncology.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

N. Girard, M. Ahn, Melissa L. Johnson, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer

A. Mansfield, T. Mok, Melissa L. Johnson, 2018, The New England journal of medicine.

Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration

Melissa L. Johnson, J. Grilley-Olson, S. Hu-Lieskovan, 2021, Targeted Oncology.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

P. Jänne, D. Root, R. Heist, 2021, Experimental and Molecular Therapeutics.

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

P. Jänne, S. Ou, J. Christensen, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract CT224: Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non small cell lung cancer (NSCLC)

R. Coffman, R. Janssen, Melissa L. Johnson, 2019, Clinical Trials.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

C. Rudin, R. Govindan, Melissa L. Johnson, 2017, The Lancet. Oncology.

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.

J. Christensen, Melissa L. Johnson, R. Yaeger, 2022, Journal of Clinical Oncology.

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas

M. Ladanyi, C. Sima, M. Kris, 2013, Cancer.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

J. Fernandez-Banet, A. Pavlícek, J. Christensen, 2019, Cancer discovery.

Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma progressing on or after a PD-1/L1 blocking antibody.

P. Danaher, R. Sullivan, E. Schmidt, 2018 .

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

Melissa L. Johnson, M. Agulnik, Melissa Johnson, 2013, OncoTargets and therapy.

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

Vamsidhar Velcheti, Philip J. Stephens, Vincent A. Miller, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2020 .

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2022, Journal for ImmunoTherapy of Cancer.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

G. Shapiro, Melissa L. Johnson, S. Moody, 2021 .

Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

A. Iafrate, P. Stephens, A. Shaw, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer.

Sonali M. Smith, R. Schilsky, H. Mackay, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial.

Melissa L. Johnson, J. Grilley-Olson, S. Hu-Lieskovan, 2019, JAMA oncology.

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017 .

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial

A. Shaw, Melissa L. Johnson, E. Felip, 2017, The Lancet. Oncology.

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

B. B. Weitner, A. Rademaker, M. Kris, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom Index.

D. Cella, Melissa L. Johnson, S. Magasi, 2013, Clinical lung cancer.

Lungs Don’t Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers

M. Ladanyi, C. Sima, M. Kris, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.

M. Ladanyi, C. Azzoli, Melissa L. Johnson, 2011, Lung cancer.

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

R. Coffman, Melissa L. Johnson, L. Bazhenova, 2021, Clinical Cancer Research.

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

Melissa L. Johnson, L. Byers, A. Navarro, 2021, Clinical lung cancer.

Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.

Melissa L. Johnson, C. H. van der Leest, B. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Melissa L. Johnson, G. Weiss, I. Lowy, 2019, Clinical Cancer Research.

Complex decisions for first-line and maintenance treatment of advanced wild-type non-small cell lung cancer.

Melissa L. Johnson, R. Gentzler, M. Johnson, 2015, The oncologist.

Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.

M. Ladanyi, C. Sima, M. Kris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.

Melissa L. Johnson, J. Patel, M. Johnson, 2014, Seminars in oncology.

513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors

Toshio Shimizu, Melissa L. Johnson, M. R. Patel, 2021, Annals of Oncology.

First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

K. Kelly, Melissa L. Johnson, Huanyu Chen, 2019, Journal of Clinical Oncology.

Cemiplimab (REGN2810): A fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study.

Melissa L. Johnson, T. Owonikoko, I. Lowy, 2017 .

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Melissa L. Johnson, K. Papadopoulos, Sang-We Kim, 2021 .

Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib

Melissa L. Johnson, L. Bazhenova, Jun Zhang, 2023, The oncologist.

OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer

A. Drilon, B. Tuch, T. Mok, 2018, Journal of Thoracic Oncology.

A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.

A. Drilon, Keunchil Park, Melissa L. Johnson, 2018 .

A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab ± Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.

Melissa L. Johnson, G. Curigliano, D. Morgensztern, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

F. Cappuzzo, Michael Thomas, F. Shepherd, 2017, Lung cancer.

Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.

Melissa L. Johnson, D. Hong, P. Fracasso, 2020 .

ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma

Melissa L. Johnson, D. Hong, K. Odunsi, 2019, Annals of Oncology.

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

J. Blay, G. Demetri, Melissa L. Johnson, 2021 .

Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).

D. Carbone, Melissa L. Johnson, S. Ramalingam, 2020, Clinical lung cancer.

Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)

G. Linette, Melissa L. Johnson, M. Edelman, 2019, Clinical Trials.

First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers

Adam R Ferguson, C. Drake, D. Carbone, 2019 .

Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

C. Sima, M. Kris, C. Azzoli, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

F. Bushman, Melissa L. Johnson, B. V. Van Tine, 2023, Nature Medicine.

Emerging targeted therapies for breast cancer.

Melissa L. Johnson, A. Seidman, Andrew D Seidman, 2007, Hematology/oncology clinics of North America.

Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.

Melissa L. Johnson, R. Cohen, M. Gillison, 2021 .

First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results

Melissa L. Johnson, J. Bendell, G. Falchook, 2019, Annals of Oncology.

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Michael Thomas, Melissa L. Johnson, K. Yoh, 2021 .

SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.

C. Rudin, Melissa L. Johnson, D. Brickman, 2020, Lung cancer.

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Philip J. Stephens, James X. Sun, Garrett M. Frampton, 2016 .

ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.

E. Schmidt, Melissa L. Johnson, Douglas B. Johnson, 2018 .

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.

G. Giaccone, C. Azzoli, R. Govindan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and preliminary antitumor activity of U3-1402: A HER3-targeted antibody drug conjugate in EGFR TKI-resistant, EGFRm NSCLC.

P. Jänne, Melissa L. Johnson, Channing Yu, 2019, Journal of Clinical Oncology.

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).

Melissa L. Johnson, D. Nuyten, Kang-Yun Lee, 2022, Journal of Clinical Oncology.

PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

N. Reinmuth, T. Mok, Melissa L. Johnson, 2021, Journal of Thoracic Oncology.

278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2020 .

359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

R. Govindan, A. Chiang, R. Salgia, 2020 .

A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).

Melissa L. Johnson, G. Weiss, I. Lowy, 2016 .

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Y. Drew, J. Machiels, Melissa L. Johnson, 2019, Clinical Cancer Research.

A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors.

Melissa L. Johnson, R. Gonzalez, A. Gollerkeri, 2017 .

Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data

Melissa L. Johnson, T. Owonikoko, K. Papadopoulos, 2018, SKIN The Journal of Cutaneous Medicine.

Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC).

C. Rudin, R. Govindan, Melissa L. Johnson, 2016 .

Comparison of the KRAS/EGFR mutation profile and survival of “collegiate smokers” and never smokers with advanced lung cancers.

M. Ladanyi, A. Drilon, C. Sima, 2012 .

Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

C. Sima, M. Kris, C. Azzoli, 2014, Cancer biomarkers : section A of Disease markers.

Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

R. Doebele, Melissa L. Johnson, M. Gounder, 2022, Cancer Research.

404 Initial biomarker and clinical data of a phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: cohort of subjects with checkpoint inhibitor-naïve advanced MSS-colorectal cancer

Melissa L. Johnson, N. Le, A. Naing, 2021, Journal for ImmunoTherapy of Cancer.

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.

J. Nieva, Melissa L. Johnson, L. Byers, 2021, Journal of Clinical Oncology.

BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.

A. Tolcher, Melissa L. Johnson, D. Rasco, 2021 .

Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.

B. Halmos, Melissa L. Johnson, J. Strauss, 2023, Clinical lung cancer.

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

R. Govindan, Melissa L. Johnson, E. Felip, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)

R. Govindan, Melissa L. Johnson, T. Owonikoko, 2021 .

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC

P. Jänne, Melissa L. Johnson, M. Nishio, 2020 .

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies.

Suzanne F. Jones, Melissa L. Johnson, D. Spigel, 2023, The oncologist.

EGFR mutations in men and cigarette smokers with lung adenocarcinoma.

M. Ladanyi, M. Kris, V. Rusch, 2010 .

Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial

C. Dooms, Melissa L. Johnson, S. Novello, 2023, The Lancet.

OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study

P. Jänne, S. Gettinger, Melissa L. Johnson, 2017 .

A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.

Suzanne F. Jones, Melissa L. Johnson, H. Burris, 2019, Journal of Clinical Oncology.

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

Suzanne F. Jones, Melissa L. Johnson, G. Fabbri, 2023, British Journal of Cancer.

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Suzanne F. Jones, Melissa L. Johnson, J. Sachdev, 2023, Investigational New Drugs.

P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

Melissa L. Johnson, B. Cho, R. Meng, 2021 .

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC).

A. Tolcher, T. Burns, Melissa L. Johnson, 2020 .

A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

S. Ou, D. Potvin, J. Christensen, 2019, Journal of Clinical Oncology.

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.

R. Sullivan, R. Govindan, Melissa L. Johnson, 2018 .

Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy

R. Sullivan, Melissa L. Johnson, M. Opyrchal, 2019, Clinical Trials.

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

Jie Yang, C. Rudin, Melissa L. Johnson, 2023, Journal of Hematology & Oncology.

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021 .

ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma.

E. Schmidt, Melissa L. Johnson, M. Opyrchal, 2017 .

A Phase Ib, Open-Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumors: Expansion Cohorts.

Suzanne F. Jones, J. Barrett, Melissa L. Johnson, 2016 .

1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)

Melissa L. Johnson, O. Gardner, H. Gilbert, 2020, Annals of Oncology.